To evaluate the short-term effects of sibutramine on appetite and eating behaviour and whether these effects are related to the long-term therapeutic outcome. STUDY DESIGN: Short-term: randomised, double-blind, placebo-controlled, within-subject design. At baseline, the subjects were treated for 14 days with 15 mg sibutramine/placebo (period 1) followed by a 2 weeks single-blind placebo washout period, the subjects received the alternative therapy for another 14 days (period 2). At baseline, and at day 14 in each treatment period the subjects arrived fasting to the laboratory for a standardised breakfast and an ad libitum standardised lunch using the VIKTOR set-up (a universal eating monitor) to evaluate the microstructure of the eating behaviour (ie amount of food consumed and eating rate). Visual Analogue Scales were applied before and after the meals as well as every hour between the meals to monitor the appetite. During this first phase, subjects were encouraged to keep their habitual eating habits. Second phaseFlong-term effects: All subjects received 10 months open treatment with 15 mg sibutramine and dietary advice in monthly group sessions with a dietitian. On the last day of this treatment period, the subjects returned to repeat the measurements of appetite and eating behaviour using the same test procedure as during the first phase of the study. RESULTS: First phase: Sibutramine influenced appetite and eating behaviour that could be registered after only 14 days of treatment. The amount of food consumed at lunch on VIKTOR was reduced by 16% by sibutramine compared to placebo, 3357123 g vs 3997126 g (Po0.0001). Second phase: Responders and nonresponders were defined as those who ate less vs more food on VIKTOR when treated with sibutramine compared to the baseline food intake in the first phase of the study. The weight reduction was greater for responders 11.876.2 (mean7s.d.) kg compared to nonresponders 6.872.7 (mean7s.d.) kg (Po0.05). CONCLUSION: Short-term effects of sibutramine on appetite and eating behaviour were identified such as a reduction in food intake and in ratings of subjective motivation to eat. Short-term sibutramine effects on eating behaviour are to some extent related to the long-term therapeutic outcome in obese subjects.
Introduction
Obesity has become a major health problem worldwide. 1 An important task is to prevent this obesity epidemic, and also to find efficient long-term treatment programmes for the already obese. The development of obesity is determined by genetic, biological, environmental, social, psychological and ethnical factors, but the relative contribution and importance of each such factor varies greatly among individuals. The obese are not a homogenous group and therefore there is no single ideal treatment programme available. A range of different treatment approaches exist: from behavioural modification and cognitive therapy to surgical therapy and different pharmacological approaches.
One recent addition to the treatment arsenal is sibutramine, a serotonin and noradrenaline reuptake inhibitor (SNRI). Sibutramine exerts its weight-reducing effects mainly by reducing the appetite, but also to some extent by increasing thermogenesis. 2 The long-term weight reducing effect of sibutramine is well established, 3 and the drug is also effective in sustaining weight maintenance after weight loss. 3 In order to offer each patient optimal treatment a common clinical experience is that there is an urgent need to find predictors for successful treatment outcome. 4 If sibutramine's appetite-reducing effects are measurable already after a short term, these appetite measurements could further be tested in relation to the long-term therapy outcome. Thus, the aim of the first phase of the study was to evaluate the short-term effects of sibutramine on appetite, using objective as well as subjective measurements. The primary aim of the second part of the study was to evaluate the relation between the appetite measurements and the long-term weight reduction.
Subjects and methods
A randomised, double-blind, placebo-controlled, crossover design was conducted in the first phase of the trial. The second phase of the trial was open and all subjects received active medication (15 mg sibutramine) for 10 months.
Male and female patients from 20 to 65 y with a body mass index (BMI) between 30 and 45 kg/m 2 were recruited from the waiting list to the outpatient Obesity unit at the Huddinge University Hospital after informed consent had been obtained. The main exclusion criteria were endocrine causes of obesity, cardiovascular disorders including hypertension and/or arrythmia, treatment with drugs that might interfere with the sibutramine action or other conditions where sibutramine treatment is contraindicated according to the general clinical routines (eg betablockers and SSRIs). Participation was stopped if patients became pregnant, presented with concomitant severe disease, suffered severe adverse events, withdrew their informed consent or failed to attend the clinical appointments during the first phase of the study.
A total of 38 subjects were initially included in the study. Two subjects were withdrawn from the study within 2 weeks from study start: one woman because of pregnancy, and one woman because she failed to attend on the first test days. Thus, 36 subjects (nine males/27 females) aged 44.1712.1 (mean7s.d.) y with BMI 39.374.3 kg/m 2 (range 39.2 -45.2) were eligible for the evaluation of the first phase of the study. All 36 subjects entered the second phase of the study and 27 (20 women/seven men) of them completed the full 10 months period. One patient was excluded because of hypertension. The remaining eight dropped out because of the following subjective reasons given: two subjects because of dry mouth, one because of insomnia and the other five because of administrative reasons (eg lack of time to participate at the monthly group sessions) and/or insufficient therapeutic response (eg subjects considered their weight loss progress to be less than they had expected).
Study medication
Sibutramine (15 mg) and placebo were supplied in identical opaque white capsules in coded bottles. Subjects were instructed to take their daily dose of medication in the morning by swallowing the whole capsule with water before breakfast.
Measurements of appetite and eating behaviour
The main effect variable in this study was the single-meal intake of food (measured by VIKTOR), which was regarded as an objective measurement of the effect of appetite of sibutramine. The VIKTOR equipment consists of a hidden scale built into a table and connected to a computer. A plate with a homogenous meal in excess is placed on top of the scale and the subjects are instructed to eat until satisfied. After the meal is finished the computer calculates the microstructure of the eating behaviour, that is the total food intake in grams, meal duration in minutes and eating rate as grams per minute. The stability of these eating variables has been tested previously and over five eating occasions both relative (test-retest) and absolute (F-test) stability has been found in both obese and normal weight men and women. 5, 6 The intraindividual coefficient of variation (CV) calculated on the same population (76 subjects) is 14% for the variable food intake and 14% for eating rate. The eating curve is also fitted to a polynomial. Twice the quadratic coefficient represents the rate of deceleration. 7 A negative coefficient illustrates a decelerating eating curve, an eating curve where the eating rate slows down towards the end of the meal. The decelerating eating curve is the most common type of eating curve and has also been called the biological satiating curve. 8 A positive coefficient represents an accelerating eating curve. Assessments of subjective feelings of appetite that is desire to eat, hunger, satiety and how much they could eat (prospective consumption) were made by Visual Analogue Scales (VAS). 6, 9 For example, the question 'How strong is your desire to eat now?' was rated along a 100 mm scale anchored with 'Not strong at all' on the left and 'Very, very strong' on the right.
Meals
The standardised breakfast, which had to be entirely consumed by the subjects, consisted of two slices of wholemeal bread (90 g), low-fat margarine (10 g 
Procedure
First phaseFshort-term effects of sibutramine vs placebo. At baseline, subjects were randomly assigned to sibutramine (15 mg) or placebo for 14 days (period 1), and after a 2 week single-blind placebo washout period, the subjects switched to the alternative therapy for another 14 days (period 2) (see Figure 1 ). At baseline, and on the 14th day of each treatment period, the subjects arrived fasting to the laboratory in the morning for a test day (at the same hour each test day). Body weight, blood pressure, pulse rate and any adverse events were assessed, and a pregnancy test performed. A fasting blood sample was collected for subsequent analysis of glucose, insulin and lipids (triglycerides, HDL and LDL) before the standardised breakfast was served. At 4 h after the start of the breakfast, an ad libitum standardised lunch meal was served on VIKTOR with a glass of water (200 ml). Patients were asked to eat until satisfied and to drink the glass of water. VAS to monitor the appetite were applied immediately before and after the meals, as well as every hour between the meals. The subjects were informed that they were participating in a 6 week long double-blind study with within-subject design, to examine the effect of the drug on appetite, but that neither we nor they would know when they received the different study medications. No mention that food intake was measured by VIKTOR was made until the end of the study. Subjects were asked to keep their habitual eating habits and physical activity level during the whole 6 weeks long trial and not to change anything during this time period. We also asked them to keep the same habits according to working hours, physical habits and eating pattern prior to test days.
Second phaseFlong-term effects of sibutramine treatment.
Immediately after the second test day during the first phase of the study all subjects received 10 months of open treatment with 15 mg of sibutramine. During this 10 months period, all subjects participated monthly in group sessions with a dietitian relating to nutritional education, food choices, cooking methods as well as behavioural modification methods in order to improve weight reduction and weight maintenance. If subjects are compliant with the recommendations given at these sessions, they will obtain about 15-20% of their daily energy from protein, not more than 30 E% from fat and 50-55% of their daily energy intake from carbohydrates, all according to the Nordic Nutrition Recommendations (1996). 10 In conjunction with these monthly sessions, a nurse assessed body weight, blood pressure, pulse rate, recorded any adverse event as well as handled study medication and performed pregnancy tests.
On the last day of the 10-month period of open treatment with sibutramine, the subjects came for a test day for measurements of appetite and eating behaviour, where the procedure from the first phase of the study (see above) was repeated.
The staff and the subjects were blinded to the results from the first phase and also during the second phase of the study.
Adverse events
All adverse events were recorded, including type, severity, dates of onset and resolution as well as the relation of the adverse event to study medication.
Statistics
First phase: The statistical package Statistica 5.5 and SAS (Statistical Analysis Systems Inc., Cary, NC, USA) was used for the statistical analysis. Repeated measures two-way analysis of variance (ANOVA) was used to analyse experimental and laboratory data with treatment (placebo/ active) and time period (baseline/period 1/period 2) as main factors. Two-way ANOVA was also used to analyse the VAS ratings (Visual Analogue rating Scales) in the two different periods separately with treatment and time as main factors. Student's t-test was used to test individual means. w 2 test was used to test the number of decelerated eating curves. Second phase: Student's t-test was used to compare longterm treatment effects of sibutramine with baseline data. For evaluating the relation between short-term effects on food intake on long-term outcome on weight, correlations (Pearson's R) were used for continuous data and the MannWhitney test was used for comparing weight loss for responders and nonresponders. A nonparametric test was chosen because of skewness in the number of subjects in each of the groups. Short-term effects of sibutramine B Barkeling et al
Results
First phaseFshort-term effects of sibutramine vs placebo Eating behaviour. The intake of food at baseline, and on the test days during the first and the second period, with the different study medications are shown in Figure 2 and in Table 1 . The subjects receiving sibutramine during period 1 decreased their intake of food by 19% compared to baseline measurements and when this group received placebo, their intake of food returned to baseline level. The subjects receiving placebo during the first period also reduced their intake of food by 8% compared to baseline. When this group received sibutramine during period 2, their intake was reduced by 16% compared to baseline. The statistical analysis with ANOVA, including baseline and the two test days, showed a significant difference in intake between the different time periods as well as for different treatments (Po0.001). When baseline measurements were excluded and analyses performed between sibutramine and placebo, the active drug reduced food intake by 16% (Po0.0001, paired Student's t-test). The eating rate and the occurrence of decelerated vs accelerated eating curves were unaffected by the treatment (see Table 1 ).
VAS ratings of appetite. Using Visual Analogue rating Scales measuring motivation to eat (appetite), there was no significant difference in ratings between sibutramine and placebo for any of the following scales: desire to eat (P ¼ 0.62), hunger (P ¼ 0.35), fullness (P ¼ 0.89) and prospective consumption (P ¼ 0.75) during period 1. During period 2 when the initial placebo effect was not present, there was an obvious reduction in appetite when sibutramine was compared to placebo for the rating scale measuring the desire to eat (Po0.05). The same trend towards a reduction was seen for prospective consumption (P ¼ 0.057) and the scale measuring hunger (P ¼ 0.079). The ratings for the scales measuring desire to eat during periods 1 and 2 are shown in Figure 3a and b, respectively.
Anthropometric data. Anthropometric data at baseline and after 14 days with sibutramine and placebo are presented in Table 1 . The statistical analysis with ANOVA showed a significant difference in weight between different time periods as well as in relation to treatment (Po0.01). When baseline measurements were excluded in the analyses there was a significant reduction in weight when sibutramine was compared to placebo (Po0.01; paired Student's ttest).
Adverse events. The most frequently reported adverse event during the short-term period of the study was dry Figure 2 The intake of food at lunch (mean7s.d.) measured by VIKTOR at baseline, and on test days during periods 1 and 2, with the different study medications. The reduction of food is given as a percentage. Short-term effects of sibutramine B Barkeling et al mouth, reported by 12 subjects on sibutramine, but also by four subjects on placebo. Insomnia was reported by six subjects on sibutramine, and by one subject on placebo. Anxiety was reported by two subjects when on sibutramine, headache by two subjects on sibutramine and by three subjects on placebo. Constipation was only reported by one subject while taking placebo. Palpitations were reported by one subject during the sibutramine period and by one during placebo.
Second phaseFlong-term effects of sibutramine treatment Eating behaviour. After 10 months of treatment with sibutramine the intake of food measured by the VIKTOR equipment was reduced by 27% compared to baseline measurements, that is 300787 vs 4087146 g (Po0.01). The smaller food intake after treatment was because of a shorter duration of consumption, 7.972.5 min vs 10.273.0 min (Po0.001) as the eating rate was the same after 10 months of treatment compared to baseline, 42716 vs 42713 g/min (NS). The number of subjects with decelerated and accelerated eating curves was also the same.
VAS ratings of appetite
Statistical analyses for the Visual Analogue rating Scales measuring appetite were performed for the time points immediately after the standardised breakfast and immediately before lunch. After breakfast, there was a clear decrease in appetite ratings for fullness (Po0.05) and increase in ratings of prospective consumption (Po0.05) and hunger (P ¼ 0.052) after 10 months with sibutramine treatment compared with baseline values. The ratings immediately before lunch also showed the same trend towards a reduction in appetite when on sibutramine but with no statistical significant differences compared to baseline.
Weight, waist and metabolic changes. In Table 2 , data on anthropometric data at baseline and after 10 months of treatment with sibutramine are presented for the 27 completers. After 10 months, a mean weight loss of 10% (10.9 kg) had been achieved as well as significant reduction in BMI and waist circumference compared to baseline. When the same analysis was performed for all 36 patients initially included using the principal of 'last observation carried forward' the mean weight reduction was 8.2 kg or 7.2%. There were substantial decreases in fasting levels of glucose (from 6.172.3 to 5.470.9 mmol/l, Po0.05), insulin (from 95737 to 73728 mU/l, Po0.01) and triglycerides (from 1.670.7 to 1.270.5 mmol/l, Po0.001), but not in concentrations of LDL or HDL cholesterol. The blood pressure recordings tended to decrease over the 10-month period, but the observed differences were not significant (À5 mmHg, P ¼ 0.054).
The sequential mean weight changes during the 10 months of open treatment with sibutramine are shown in Figure 4 .
Short-term effects and long-term therapeutic outcome. In order to evaluate if the short-term effects of sibutramine on eating behaviour and appetite are related to the long-term Figure 3 Subjective ratings of motivation to eat, that is appetite on Visual Analogue rating scales (100 mm) at different time points of the test day for the scales measuring desire to eat during period 1 (a) and period 2 (b). Short-term effects of sibutramine B Barkeling et al therapeutic outcome, that is weight loss, groups of 'responders' and 'nonresponders' were defined. Responders regarding eating behaviour were defined as those who ate less food on VIKTOR, when on sibutramine compared to their baseline food intake. Accordingly, nonresponders were defined as the opposite. When the mean weight reduction at 10 months was compared between the two groups, responders (n ¼ 22) had lost 11.876.2 (mean7s.d.) kg (median 12.0 kg) and nonresponders (n ¼ 5) 6.872.7 (mean7s.d.) kg (median 8.1 kg), (Po0.05, Mann-Whitney test). Of the eight subjects who dropped out during the second phase of the study, six were responders (see definition above) and two were nonresponders. Of these six responders, three had lost weight and three had gained weight at their last attendance (ranging from month one to seven) in the study. Of the two nonresponders who dropped out, one had lost weight and one had gained weight at their last attendance (at month 6 and 1, respectively). A scattergram showing the correlation between the reduction in food intake on VIKTOR when on sibutramine vs baseline during the first phase and the long-term weight loss is shown in Figure 5 . If all 27 subjects are included in the statistical analysis the r-value is 0.09 (NS). In this scatterplot, two statistical outliers were suggested by visual estimations, that is the subject who lost the most weight and the subject who gained the most weight. Further, box plot analyses revealed that these cases were the highest and lowest extreme outliers on the weight reduction variable. If these outliers are excluded in the statistical analyses, the r-value would be 0.53 (Po0.01).
In order to obtain an 'appetite index' the ratings for each of the different types of appetite scales (eg desire to eat, hunger, satiety and prospective consumption) from all the seven time points were added and divided by seven. Responders were defined as those who had lower appetite index when on sibutramine compared to baseline (less desire to eat, less hunger, felt more full or thought they could eat less), and nonresponders defined as those with higher scores when on sibutramine compared to baseline. For all four different scales the weight reduction was greater for responders compared to nonresponders (Mann-Whitney tests), although not statistically different.
Discussion
In this study, sibutramine reduced the intake of food and subjective motivation to eat. The short-term changes in the intake of food are to some extent related to the long-term weight reduction results in obese subjects.
The VIKTOR equipment, as an objective measurement of appetite, together with rating scales measuring subjective motivation to eat, has previously been used in a number of studies with within-subject design to test and document effects of drugs, dietary manipulations or other treatments on appetite and satiety. 5, 6, [11] [12] [13] [14] [15] [16] [17] The explanation for the decreased food intake during treatment with sibutramine is not likely to be a normal variability of the eating behaviour. Data on the reproducibility of the VIKTOR measurements have shown that variables such as eating rate and amount of food eaten are stable over time, if physical habits and eating patterns are controlled before test meal. 6 The short-term effects of sibutramine on food intake in obese subjects have been studied previously and our findings are in accordance with these results. Rolls and collaborators used a test meal of 'smorgasboard type' consisting of a variety of standardised dishes. They also compared two different doses of sibutramine 10 and 30 mg with placebo, and found that the intake of food was reduced by 19 and 26%, respectively, after 14 days of treatment. 18 A placebo effect was detected in the present study during the first 14 days of the study. The reduction in intake and appetite ratings compared to placebo would probably have been greater if this placebo effect, probably because of high Short-term effects of sibutramine B Barkeling et al expectations on treatment, had not been present. We believe it was interesting to document such an effect. A run-in period with placebo prior to the actual start of the study could possibly have been one way to eliminate such an effect. When analysing the long-term effects of sibutramine treatment on subjective motivation to eat measured repeatedly with VAS on test days, ANOVA (repeated measures) cannot be applied, nor multiple comparisons with t-tests, because of the likelihood of mass significances. Thus, we had to choose a maximum of two time points of interest to compare over time: one time point prior to a meal and one time point after a meal. We chose the time point after breakfast and not before lunch, since the size of the breakfast meal was equal for all subjects but not the size of the lunch meal intake. We chose 'before lunch' since the trial conditions up to that time point were standardised for all subjects and the possible effects of biological rhythm (morning vs night traits) would also be wiped out.
When the subjective VAS ratings for appetite from the first phase of the study were used to compare groups of 'responders' and 'nonresponders', there was a trend towards a greater long-term weight reduction in the former. The number of nonresponders was however very small and a larger sample may have resulted in a statistically significant difference.
Most clinical trials on weight-reducing drugs combine drug administration with dietary advice prescribing a reduced energy intake. Thus, in the present study monthly group sessions with a dietitian was also included in the second open phase of the study. How much of the achieved weight loss on sibutramine could be attributed to the drug and the dietary intervention, respectively? The placebo-controlled trials with sibutramine including energy restriction have after 6 months resulted in almost no changes in weight when on placebo þ dietary intervention compared to a weight reduction of 4-12% when on sibutramine+dietary intervention. 2 Thus, it seems like the major part of the weight loss could be attributed to the actual drug. There are several comorbid conditions associated with obesity including type II diabetes, coronary heart disease (CHD), dyslipidaemia and hypertension. Weight reduction improves blood glucose dramatically in diabetes and also reduces several risk factors for CHD 3, 19 and should therefore be considered a first-line therapy. In this study, long-term treatment with sibutramine was associated with a significant reduction not only in weight and BMI but also in waist circumference, which is a marker for increased risk for metabolic comorbid conditions not only in the obese, but also in overweight people. Despite our patients being primarily selected to the study for obesity treatment, rather than for associated complications, we found significant reductions in fasting plasma glucose (À11%), insulin (À23%) and triglyceride levels (À25%).
These findings indicate a lowered risk for the development of CHD and diabetes. In contrast to other studies, 3, 20 no significant changes in total cholesterol, LDL-cholesterol or HDL-cholesterol levels were seen when baseline values were compared with 10 months data. This discrepancy can be explained by the selection of patients with baseline values being within the normal range for these parameters. An alternative explanation could be that our treatment period was shorter than in other studies. 3, 20 Interestingly, we found that weight loss continued throughout the 10 months treatment period with only a slight tendency to attenuate during the last month. This is also in accordance with data from the STORM study, 3 but in contrast to many other obesity treatment programmes where most of the weight loss is achieved during the first 6 months of treatment. 21 In conclusion, the short-term effects of sibutramine on appetite and eating behaviour can be identified by means of the VIKTOR equipment and Visual Analogue rating Scales. The short-term reduction in food intake when on sibutramine are to some extent related to the long-term therapeutic outcome, that is weight reduction, in obese subjects.
Sibutramine is a well-tolerated and effective treatment in promoting weight loss in obese patients. Sibutramine also improves several risk markers such as waist circumference, insulin levels, glucose levels and triglycerides associated with obesity.
